Presented positive interim results at ASCO 2022 from ongoing zotatifin Phase 1/2 dose escalation and expansion trial
Appointed Doug Warner, M.D., as chief medical officer
Read more at globenewswire.comAll information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
Presented positive interim results at ASCO 2022 from ongoing zotatifin Phase 1/2 dose escalation and expansion trial
Appointed Doug Warner, M.D., as chief medical officer
Read more at globenewswire.com| Symbol | Last | Chg | %Chg |
|---|---|---|---|
| EFTR | 0.0002 | unch | unch |
| Effector Therapeutics Inc | |||